menu search

GNPX / Genprex announces opening of patient enrollment for its Acclaim-2 clinical trial

Genprex announces opening of patient enrollment for its Acclaim-2 clinical trial
Genprex Inc said it has opened patient enrollment for its Acclaim-2 clinical trial evaluating the company's lead drug candidate, REQORSA Immunogene Therapy. Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA Immunogene Therapy in combination with Keytruda (pembrolizumab) in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda. Read More
Posted: Mar 31 2022, 09:54
Author Name: Proactive Investors
Views: 103135

GNPX News  

GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know

By Zacks Investment Research
September 4, 2023

GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know

GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st more_horizontal

Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancers

By Proactive Investors
July 5, 2023

Genprex granted Chinese patent for lead drug candidate REQORSA with PD-1 antibodies to treat cancers

Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead dru more_horizontal

Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA

By Proactive Investors
June 28, 2023

Genprex shares rise as FDA grants third Fast Track Designation for small cell lung cancer therapeutic REQORSA

Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Dru more_horizontal

Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study

By Zacks Investment Research
June 1, 2023

Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study

Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer. more_horizontal

Genprex wins approval to advance Phase 2 expansion of Acclaim-1 trial of REQORSA combined with Tagrisso in advanced non-small cell lung cancer

By Proactive Investors
May 30, 2023

Genprex wins approval to advance Phase 2 expansion of Acclaim-1 trial of REQORSA combined with Tagrisso in advanced non-small cell lung cancer

Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combi more_horizontal

Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting

By Proactive Investors
May 26, 2023

Genprex says positive data from Acclaim-1 clinical trial to be published at 2023 ASCO meeting

Genprex Inc. (NASDAQ:GNPX) said positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA Immunogene Therapy in combin more_horizontal

Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise

By Proactive Investors
April 19, 2023

Genprex showcases unique potential of nonparticle delivery system at cancer conference; shares rise

A research collaborator of Genprex Inc delivered a presentation highlighting the company's non-viral ONCOPREX Nanoparticle Delivery System, the compa more_horizontal

Genprex encouraged by latest reports on novel tumor suppressor

By Proactive Investors
April 18, 2023

Genprex encouraged by latest reports on novel tumor suppressor

Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug candidate REQORSA functio more_horizontal


Search within

Pages Search Results: